OCGN is trading at $1.60 (4.19% down) as the stock undergoes a technical pullback following an 11.33% rally in the previous session.
- The move follows a surge to $1.67 on June 29, which was supported by positive analyst sentiment but lacked a new catalyst to sustain the momentum during today's session.
- Canaccord recently reiterated a Buy rating while trimming its price target to $11 from $12, citing clinical data and upcoming trial catalysts as key drivers.
- With no fresh company announcements on June 30 and mixed broader market performance, the price action appears to be a consolidation of recent gains.